Neurocrine Biosciences | Driftskostnader



Operating Expenses Endring Dato
AbbVie USD 16.59B 5.96B 2024-12
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
ALKERMES USD 267.3M 6.09M 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amgen USD 6.78B 401M 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Cytokinetics USD 155.97M 14.7M 2024-12
Dynavax Technologies USD 73.66M 3.12M 2024-12
Exelixis USD 403.55M 82K 2025-01
Gilead Sciences USD 5.12B 1.54B 2024-12
Halozyme Therapeutics USD 122.51M 4.38M 2024-12
Incyte USD 877.18M 114.6M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Prothena USD 67.02M 463K 2024-12
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Repligen USD 204.05M 41.58M 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Teva Pharmaceutical Industries USD 3.77B 609M 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Neurocrine Biosciences Driftskostnader - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2025.